“Cholesterol Drugs Have No Clear Answers”
Cholesterol lowering drugs (statins) profits are at an all-time high. Drug manufacturers are determined to “statinize” the planet with cholesterol lowering medications, regardless of increasing data questioning their benefits and studies showing their harmful potential. Previously, Pfizer’s drug, tocetrapib, raised “good cholesterol” and lowered “bad cholesterol” but did not slow the progression of plaque buildup and it significantly raised blood pressure and increased the risk of death. Thus, Pfizer abandoned it. Researchers at Texas A&M University have discovered that lower cholesterol levels can actually reduce muscle gain with exercising. A 2014 article from the Medical University of Vienna found that low cholesterol may increase kidney cancer patients’ risk of dying from their disease. A new controversial 2016 study review of 19 studies involving 68,094 people, published in the BMJ Open journal, has found there is no association between what has traditionally been considered as “bad” cholesterol and the premature deaths of over-60-year-olds from cardiovascular disease. Shockingly, researchers found that 92% of the people in the study with a high cholesterol level lived longer.
